Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Johannes Bloehdorn, MD, Martin Sill, PhD, Andreas Bühler, MD, Silja Mack, MSc, Doris Winter, Lars Bullinger, MD, PhD, Arefeh Rouhi, PhD, Florian Kuchenbauer, MD, PhD, Daniel Mertens, PhD, Axel Benner, Dipl.Stat., Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 2874.

https://doi.org/10.1182/blood.V120.21.2874.2874

Published: 2012

Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Blood (2012) 120 (21): 716.

https://doi.org/10.1182/blood.V120.21.716.716

Published: 2012

Journal Articles

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Peter Dreger, MD, Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Andreas Bühler, MD, Thorsten Zenz, MD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Donald Bunjes, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MD, PhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 966.

https://doi.org/10.1182/blood.V120.21.966.966

Published: 2012

Journal Articles

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Mario Cazzola, Konstanze Döhner, MD, Jennifer Edelmann, MD, Andreas Bühler, MD, Sabrina Kless, Daniel Mertens, PhD, Raymonde Busch, Silja Mack, MSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 710.

https://doi.org/10.1182/blood.V120.21.710.710

Published: 2012

Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Blood (2011) 118 (21): 2854.

https://doi.org/10.1182/blood.V118.21.2854.2854

Published: 2011

Journal Articles

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

Blood (2010) 116 (21): 920.

https://doi.org/10.1182/blood.V116.21.920.920

Published: 2010

Journal Articles

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Andreas Bühler, MD, Thorsten Zenz, MD, Dirk Winkler, MD, Raymonde Busch, Kirsten Fischer, MD, Anna Fink, MD, Clemens Wendtner, Barbara Eichhorst, Jennifer Edelmann, MD, Michael Hallek, Hartmut Doehner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 3609.

https://doi.org/10.1182/blood.V116.21.3609.3609

Published: 2010

Journal Articles

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Thorsten Zenz, MD, Peter Dreger, MD, PhD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Matthias Ritgen, MD, Dirk Winkler, MD, Andreas Bühler, MD, Donald Bunjes, MD, Dietrich Beelen, MD, Sandra Cohen, MD, FRCPC, Ute Hegenbart, MD, Matthias Zeis, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 2357.

https://doi.org/10.1182/blood.V116.21.2357.2357

Published: 2010

Journal Articles

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

Thorsten Zenz, MD, Raymonde Busch, Anna Fink, MD, Dirk Winkler, MD, Kirsten Fischer, MD, Andreas Bühler, MD, Patrick Hoth, Gunter R. Fingerle-Rowson, MD, PhD, Michael Kneba, MD, PhD, Sebastian Boettcher, MD, Ulrich Jäger, MD, Myriam Mendila, MD, Michael Wenger, MD, Peter Lichter, PhD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2010) 116 (21): 2427.

https://doi.org/10.1182/blood.V116.21.2427.2427

Published: 2010

Journal Articles

In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.

Thorsten Zenz, Matthias Volden, Theresa Mast, Antonio Sarno, Dirk Winkler, Andrea Schnaiter, Andreas Bühler, Christian Klein, Pablo Umana, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 2379.

https://doi.org/10.1182/blood.V114.22.2379.2379

Published: 2009

Journal Articles

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Thorsten Zenz, Antonio Sarno, Andrea Schnaiter, Dirk Winkler, Andreas Bühler, Matthias Volden, Connie L. Erickson-Miller, Yasser Mostafa Kamel, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 4408.

https://doi.org/10.1182/blood.V114.22.4408.4408

Published: 2009

Journal Articles

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Blood (2009) 114 (22): 1267.

https://doi.org/10.1182/blood.V114.22.1267.1267

Published: 2009

Journal Articles

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Raymonde Busch, Günther Fingerle-Rowson, Kirsten Fischer, Anna- Maria Fink, Ulrich Jäger, Sebastian Böttcher, Michael Kneba, Michael Wenger, Myriam Mendila, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 781.

https://doi.org/10.1182/blood.V112.11.781.781

Published: 2008

Journal Articles

17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution

Thorsten Zenz, Antonio Sarno, Sonja Häbe, Tina Denzel, Julia Mohr, Dominik Vollmer, Maria Heuberger, Dirk Winkler, Dirk Kienle, Andreas Bühler, Sim Truong, Nancy Patten, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2008) 112 (11): 782.

https://doi.org/10.1182/blood.V112.11.782.782

Published: 2008

Journal Articles

The Response to DNA Damage in CLL Cells Is Partly Determined by the Type of TP53 Mutation and Genomic Aberrations

Julia Mohr, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Daniel Mertens, Hartmut Döhner, Stephan Stilgenbauer, MD, PhD

Blood (2008) 112 (11): 3119.

https://doi.org/10.1182/blood.V112.11.3119.3119

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Juergen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz H. Truemper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 329.

https://doi.org/10.1182/blood.V112.11.329.329

Published: 2008

Journal Articles

Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.

Thorsten Zenz, Julia Mohr, Eric Eldering, Arnon P Kater, Andreas Bühler, Dirk Winkler, Dirk Kienle, Jan Dürig, Daniel Mertens, Hartmut Döhner, Stephan Stilgenbauer

Blood (2008) 112 (11): 1209.

https://doi.org/10.1182/blood.V112.11.1209.1209

Published: 2008

Journal Articles

Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.

Stephan Stilgenbauer, Barbara F. Eichhorst, Raymonde Busch, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Valentin Goede, Clemens M Wendtner, Peter Lichter, Berthold Emmerich, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 2089.

https://doi.org/10.1182/blood.V112.11.2089.2089

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

Stephan Stilgenbauer, Dirk Winkler, Andreas Bühler, Thorsten Zenz, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Jürgen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz Trümper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2007) 110 (11): 3120.

https://doi.org/10.1182/blood.V110.11.3120.3120

Published: 2007

NARROW

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution

The Response to DNA Damage in CLL Cells Is Partly Determined by the Type of TP53 Mutation and Genomic Aberrations

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.

Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.

Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only